BIOMAT Database Logo BIOMAT Database Logo

LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. 2012

Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, PR China.

The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas. However, a considerable number of glioblastoma (GBM) cases are refractory to TMZ. Previous studies have revealed that the PI3K/Akt pathway is activated in an ataxia telangiectasia and Rad3 related-dependent manner in response to TMZ. Thus, we hypothesized that PI3K inhibitors may act as antitumor agents against gliomas and potentiate the cytotoxicity of TMZ. The cytotoxicity of a PI3K inhibitor, LY294002, was examined both alone and in combination with TMZ in human glioma cell lines. Proliferation of tumor cells treated with LY294002 in combination with TMZ was significantly suppressed compared to treatment with either drug used alone. The combination treatment induced a higher apoptosis rate, while reducing the invasive capability of U87 cells. The apoptosis-associated proteins, cleaved-caspase-3 and Bax, were more significantly up-regulated by the combined treatment than by TMZ used alone. In addition, p-Akt and Bcl-2, which can promote TMZ resistance, were markedly decreased by LY294002. These findings suggest that LY294002 enhances the cytotoxicity of TMZ by down‑regulation of the PI3K/Akt pathway.

UI MeSH Term Description Entries
D009025 Morpholines Tetrahydro-1,4-Oxazines,Tetrahydro 1,4 Oxazines
D002867 Chromones 1,4-Benzopyrones,Chromone,1,4 Benzopyrones
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077204 Temozolomide A dacarbazine derivative that is used as an alkylating antineoplastic agent for the treatment of MALIGNANT GLIOMA and MALIGNANT MELANOMA. 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one,CCRG 81045,CCRG-81045,M&B 39831,M&B-39831,Methazolastone,NSC 362856,NSC-362856,TMZ-Bioshuttle,TMZA-HE,Temodal,Temodar,Temozolomide Hexyl Ester,CCRG81045,M&B39831,NSC362856,TMZ Bioshuttle
D000081082 Phosphoinositide-3 Kinase Inhibitors Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. Phosphoinositide-3 Kinase Inhibitor,Inhibitor, Phosphoinositide-3 Kinase,Inhibitors, Phosphoinositide-3 Kinase,Kinase Inhibitor, Phosphoinositide-3,Kinase Inhibitors, Phosphoinositide-3,Phosphoinositide 3 Kinase Inhibitor,Phosphoinositide 3 Kinase Inhibitors
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway.
December 2018, Bioscience reports,
Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
February 2015, Molecular medicine reports,
Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Inhibition of LY294002 in retinal neovascularization via down-regulation the PI3K/AKT-VEGF pathway in vivo and in vitro.
January 2018, International journal of ophthalmology,
Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Apigenin and Temozolomide Synergistically Inhibit Glioma Growth Through the PI3K/AKT Pathway.
March 2024, Cancer biotherapy & radiopharmaceuticals,
Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
January 2015, Biological & pharmaceutical bulletin,
Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
November 2016, Cancer investigation,
Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
October 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
April 2020, Journal of cellular and molecular medicine,
Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Downregulating DNA methyltransferase 3B by suppressing the PI3K/Akt signaling pathway enhances the chemosensitivity of glioblastoma to temozolomide.
February 2024, Molecular neurobiology,
Lingchao Chen, and Lei Han, and Zhendong Shi, and Kailiang Zhang, and Yanwei Liu, and Yongri Zheng, and Tao Jiang, and Peiyu Pu, and Chuanlu Jiang, and Chunsheng Kang
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
June 2020, Cell biology and toxicology,
Copied contents to your clipboard!